<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01488747</url>
  </required_header>
  <id_info>
    <org_study_id>GFHNRC023</org_study_id>
    <nct_id>NCT01488747</nct_id>
  </id_info>
  <brief_title>Bioavailability of Fish Oils: Emulsified Versus Capsular Triglyceride</brief_title>
  <official_title>Bioavailability of Fish Oils: Emulsified vs. Capsular Triglyceride</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>USDA Grand Forks Human Nutrition Research Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>USDA Grand Forks Human Nutrition Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this investigation is to determine the relative percentage and rate
      of incorporation of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and total omega-3
      (n-3) fatty acids after ingestion of 4 emulsified flavored triglyceride fish oil supplements
      versus an encapsulated triglyceride in defined plasma lipid pools.

      The primary endpoints to be evaluated include the fatty acid composition of plasma lipids
      before and after consumption of a single dose of emulsified triglyceride based fish oil and
      triglyceride of similar n-3 compositions in capsule form. The investigators will measure
      changes in plasma phospholipid, and chylomicron fatty acids.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve for phospholipid fatty acids</measure>
    <time_frame>48 hours</time_frame>
    <description>Evaluation of the bioavailability of fatty acids from fish oil supplements</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the curve for chylomicron fatty acids</measure>
    <time_frame>48 hours</time_frame>
    <description>Evaluation of the bioavailability of fatty acids from fish oil supplements</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Healthy Adults</condition>
  <arm_group>
    <arm_group_label>Coromega Omega-3 Squeeze</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5.03 g</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Coromega Nectar</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12.22 g</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Barleans Swirl</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>17.45 g</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nordic Omega-3 Softgel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4 softgels</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Coromega Omega-3 Squeeze</intervention_name>
    <description>660 mg EPA, 434 mg DHA</description>
    <arm_group_label>Coromega Omega-3 Squeeze</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Coromega Nectar</intervention_name>
    <description>660 mg EPA, 436 mg DHA</description>
    <arm_group_label>Coromega Nectar</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Barleans Swirl</intervention_name>
    <description>660 mg EPA, 660 mg DHA</description>
    <arm_group_label>Barleans Swirl</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Nordic Omega-3 Softgel</intervention_name>
    <description>660 mg EPA, 440 mg DHA</description>
    <arm_group_label>Nordic Omega-3 Softgel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy adults ages 18 to 60.

          2. Body mass index between 22 and 32 kg/m2.

          3. Medical history (interview) demonstrating good health.

          4. Nonsmoker.

          5. Consumption of a typical American diet with no unusual dietary habits.

          6. Willingness to comply with the study protocol.

          7. Low reported n-3 intake (&lt;100 mg/d) on the Omega-3 Checklist

        Exclusion Criteria:

          1. Any active, uncontrolled medical problem.

          2. Consumption of essential fatty acid supplements within the past 6 months.

          3. Use of lipid lowering drugs.

          4. Fish consumption greater than 1 fish meal per week
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan Raatz, PhD, RD</last_name>
    <role>Principal Investigator</role>
    <affiliation>USDA Grand Forks Human Nutrition Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>USDA Grand Forks Human Nutrition Research Center</name>
      <address>
        <city>Grand Forks</city>
        <state>North Dakota</state>
        <zip>58203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.ars.usda.gov/main/site_main.htm?modecode=54-50-00-00</url>
    <description>USDA Grand Forks Human Nutrition Research Center</description>
  </link>
  <reference>
    <citation>Raatz SK, Redmon JB, Wimmergren N, Donadio JV, Bibus DM. Enhanced absorption of n-3 fatty acids from emulsified compared with encapsulated fish oil. J Am Diet Assoc. 2009 Jun;109(6):1076-81. doi: 10.1016/j.jada.2009.03.006.</citation>
    <PMID>19465191</PMID>
  </reference>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 6, 2011</study_first_submitted>
  <study_first_submitted_qc>December 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2011</study_first_posted>
  <last_update_submitted>April 21, 2016</last_update_submitted>
  <last_update_submitted_qc>April 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>USDA Grand Forks Human Nutrition Research Center</investigator_affiliation>
    <investigator_full_name>Susan Raatz</investigator_full_name>
    <investigator_title>PhD, RD, Research Nutritionist</investigator_title>
  </responsible_party>
  <keyword>Omega-3 fatty acids</keyword>
  <keyword>Phospholipid fatty acids</keyword>
  <keyword>chymlomicron fatty acids</keyword>
  <keyword>Bioavailability fo fish oil supplements in healthy adults</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

